Skip to main content

Table 7 Patient characteristics of the previous studies of erlotinib after gefitinib failure

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

   Response to gefitinib Response to erlotinib
Author No. of patients CR/PR/SD PD CR/PR/SD PD DCR (%)
Lee DH et al. 23 17 6 2 21 9
Cho BC et al. 21 10 11 6 15 29
Viswanathan A et al. 5 4 1 0 5 0
Costa DB et al. 18 16 2 4 14 22
Sim SH et al. 16 11 5 4 12 25
Chang JW et al. 1 1 0 1 0 100
Garfield DH et al. 1 1 0 1 0 100
Vasile E et al. 8 8 0 5 3 63
Gridelli C et al. 3 3 0 3 0 100
Wong AS et al. 14 9 5 5 9 36
Zhou ZT et al. 21 15 6 10 11 48
Wong MK et al. 21 18 3 12 9 57
\